

**Bulletin Number:** MMP 22-41

**Distribution:** All Providers

**Issued:** December 29, 2022

**Subject:** Updates to COVID-19 Related Cost-Sharing Exemptions and Practitioner Reimbursement Rates

**Effective:** As Indicated

**Programs Affected:** Medicaid, Healthy Michigan Plan, MIChild, Maternity Outpatient Medical Services

The Medicaid program is required to cover treatments specifically for COVID-19, including specialized equipment and therapies, and preventive therapies. This requirement is very broad and encompasses a wide array of treatments and therapies, both pharmacological and non-pharmacological.

This bulletin updates the effective period associated with the Medicaid policies that exempt COVID-19 services from cost-sharing requirements outlined in bulletins [MSA 20-17](#) and [MSA 20-49](#), and for provider reimbursement rates for COVID-19 treatment administration outlined in bulletin [MSA 20-81](#). The defined effective period will align with Sections 9811 and 9821 of the American Rescue Plan Act of 2021 (ARP) for coverage of COVID-19 treatment services.

As defined by the ARP, the updated policy provisions below are effective for dates of service on and after March 11, 2021, through the last day of the first calendar quarter that begins one year after the last day of the emergency period described in Section 1135(g)(1)(B) of the Social Security Act (the Act).

### **Cost-Sharing Exemption**

COVID-19 treatment and preventive services will be exempt from co-payments for the duration of the ARP defined effective period dates described above. Beneficiaries will not incur, and providers should not collect, co-pays for COVID-19 treatment and preventive services.

Following the expiration of the ARP defined effective period dates, Medicaid program cost-sharing requirements will revert to existing Medicaid policies and State Plan authority.

## **Practitioner Reimbursement for the Administration of COVID-19 Drugs and Biological Products**

Practitioner reimbursement rates for services associated with the administration of COVID-19 drugs and biological products will continue to be 100% of Medicare rates during the ARP defined effective period dates described above.

Following the expiration of the ARP defined effective dates, reimbursement rates for these services will revert to the payment methodologies under existing Medicaid policies and State Plan authority.

### **Manual Maintenance**


Information in this bulletin refers to information already contained in the MDHHS Medicaid Provider Manual.

### **Questions**

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Health and Human Services, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mailed to [ProviderSupport@michigan.gov](mailto:ProviderSupport@michigan.gov). When you submit an e-mail, be sure to include your name, affiliation, NPI number, and phone number so you may be contacted if necessary. Typical Providers may phone toll-free 1-800-292-2550. Atypical Providers may phone toll-free 1-800-979-4662.

An electronic copy of this document is available at [www.michigan.gov/medicaidproviders](http://www.michigan.gov/medicaidproviders) >> Policy, Letters & Forms.

### **Approved**



Farah Hanley  
Chief Deputy Director for Health